Registration - In-house Corporation

Apotex Inc. / Martin Arès, President, Apotex Canada and Rest of World (ROW)

Registration Information

In-house Corporation name: Apotex Inc.
Previous in-house corporation names
Responsible Officer Name: Martin Arès, President, Apotex Canada and Rest of World (ROW)
Responsible Officer Change History
Initial registration start date: 1996-06-26
Registration status: Active
Registration Number: 953865-452

Associated Communications

Total Number of Communication Reports: 47

Monthly communication reports in the last 6 months: 8

Version 25 of 34 (2015-07-02 to 2015-11-16)

Registration versions:

Version 25 of 34 (2015-07-02 to 2015-11-16)

Lobbying Information

Subject Matters

Aboriginal Affairs
Agriculture
Economic Development
Financial Institutions
Fisheries
Government Procurement
Health
Industry
Infrastructure
Intellectual Property
International Trade
Labour
Science and Technology
Tourism
Transportation

Subject matters added through a monthly communication report

Consumer Issues

Subject Matter Details

Legislative Proposal, Bill or Resolution

Canada-European Trade Agreement. Provide input into the Government of Canada's negotiations regarding the Canada-European Union Comprehensive Economic and Trade Agreement (CETA) with respect to pharmaceuticals, counterfeit medicines, border measures and intellectual property.

Legislative Proposal, Bill or Resolution, Policies or Program

The Bill formerly known as Bill C-393 (Canada Access to Medicines Regime) with respect to simplifying the process for pharmaceutical manufacturers to participate including sections on requirements, process, outcomes and responsibilities.

Legislative Proposal, Bill or Resolution, Regulation

Patent Act - lobby for changes on all rules and processes for the listing of generic pharmaceutical products.

Policies or Program, Regulation

Trade Agreements (NAFTA) North American Free Trade Agreement, WTO (World Trade Organization), European-Canada Free Trade Agreement policies, regulations,patents: with respect to terms, dispute settlements; pharmaceutical products policies, reviews/changes/updates; and all other changes that impact the ability to introduce products or export to other countries.

Regulation

Health Canada generic submissions review/approvals: with respect to the submission of new generic products to Health Canada and the resources, timing, structures and requirements needed to complete process.
Notice of compliance regulations (NOC): with respect to application of regulations, reviews/changes as it relates to the approval of generic drugs in Canada.

Communication Techniques

Written communication
Grass-roots communication

Government Institutions

Canadian Heritage (PCH)
Canadian International Trade Tribunal (CITT)
Competition Tribunal (CT)
Finance Canada (FIN)
Foreign Affairs, Trade and Development Canada
Health Canada (HC)
House of Commons
Industry Canada
Justice Canada (JC)
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Privy Council Office (PCO)
Revenue Canada (RC)
Senate of Canada
Solicitor General Canada (SGC)
Treasury Board Of Canada Secretariat (TBS)

Government institutions added through a monthly communication report

Competition Bureau Canada (COBU)

In-house Corporation Details

Description of activities

Apotex is a Canadian-owned pharmaceutical company which researches, develops, manufactures and distributes 300 medicines to the healthcare system and exports these to 115 countries. Apotex's 2012 Research and Development (R&D) budget was $207 million - positioning it in the top 13 companies for all industrial sectors (20% of sales).

Responsible officer name and position during the period of this registration

Jeremy Desai, President and CEO

Government funding

No government funding was received during the last completed financial year.

In-house Corporation Contact Information

Address:
150 Signet Drive
Toronto, ON M9L 1T9
Canada

Telephone number: 416-749-9300

Parent Company Information

Apotex Inc. is not a subsidiary of any other parent companies.

Subsidiary Beneficiary Information

ACCUCAPS INDUSTRIES LIMITED
- 2125 AMBASSADOR DRIVE
  WINDSOR, ON N9C 3R5
  Canada
APOPHARMA INC.
- 200 BARMAC DRIVE
  TORONTO, ON M9L 2Z7
  Canada
APOTEX FERMENTATION INC.
- 50 SCURFIELD BOULEVARD
  WINNIPEG, MB R3Y 1G4
  Canada
APOTEX INTERNATIONAL INC.
- 200 BARMAC DRIVE
  TORONTO, ON M9L 2Z7
  Canada
APOTEX PHARMACHEM INC.
- 34 SPALDING DRIVE
  BRANTFORD, ON N9C 3R5
  Canada
STARPLEX SCIENTIFIC
- 50 STEINWAY BOULEVARD
  ETOBICOKE, ON M8W 6Y3
  Canada

Lobbyists Details

Senior Officers whose lobbying activities represent less than 20% of their Duties

Jeremy Desai, President and CEO | No public offices held
Peter Hardwick, Senior Vice President, Sales & Marketing, Canada | No public offices held
JACK KAY, Vice Chairman | No public offices held
BARRY SHERMAN, CHAIRMAN | No public offices held
Jeff Watson, President of Global Generics | No public offices held
Heather West, Director of Market Access | No public offices held

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties

Elie Betito, Director of Government Relations | No public offices held

Apotex Inc.

The following names have been used on or after July 2, 2008

Name	From	To
Apotex Inc.	2009-01-23	current

The following names have been used before July 2, 2008

Apotex Inc.
APOTEX INC.

Apotex Inc.

Responsible Officer History
Responsible Officer Name	From (YYYY-MM-DD)	To (YYYY-MM-DD)
Martin Arès	2026-02-24	Current
Raymond Shelley	2025-04-29	2026-02-24
Jeff Watson	2018-01-26	2019-07-16
Jeremy Desai	2014-08-01	2017-05-16
JACK KAY	1996-06-26	2014-08-01

Date Modified:: 2026-05-11

Search and menus

Language selection

Registration - In-house Corporation

Apotex Inc. / Martin Arès, President, Apotex Canada and Rest of World (ROW)

Registration Information

Associated Communications

Version 25 of 34 (2015-07-02 to 2015-11-16)

Version 25 of 34 (2015-07-02 to 2015-11-16)

Subject Matters

Subject matters added through a monthly communication report

Subject Matter Details

Legislative Proposal, Bill or Resolution

Legislative Proposal, Bill or Resolution, Policies or Program

Legislative Proposal, Bill or Resolution, Regulation

Policies or Program, Regulation

Regulation

Communication Techniques

Government Institutions

Government institutions added through a monthly communication report

Description of activities

Responsible officer name and position during the period of this registration

Government funding

In-house Corporation Contact Information

Parent Company Information

Subsidiary Beneficiary Information

Senior Officers whose lobbying activities represent less than 20% of their Duties

Senior Officers and Employees whose lobbying activities represent 20% or more of their Duties